GSK blood cancer therapy back on the market after withdrawal

The drug will be used in combination with other medicines in patients whose cancer has resurged after an earlier line of treatment

April 18, 2025 Check out STAT+

Sponsored By

Kirsty Wigglesworth/AP STAT+ | GSK blood cancer therapy, once pulled from the market, is approved in the U.K. The therapy, which treats multiple myeloma, will be used in combination with other medicines. It is currently under review in other countries, including the U.S. By Andrew Joseph Supreme Court to hear challenge to ACA rule requiring free preventive care, cancer screenings Supreme Court to hear challenge of preventive health care coverage mandated by the Affordable Care Act. Ruling could affect millions of Americans. By Angus Chen STAT+ | Trump budget draft proposes NIH consolidation and 40% spending cut Leaked plan from Trump's Office of Management and Budget envisions eight NIH institutes and centers, down from 27 By Megan Molteni, Jonathan Wosen, and Anil Oza Adobe STAT+ | Leaked budget document outlines how Kennedy may cut up HHS to build new AHA OMB document obtained by STAT shows how billions in cuts to HHS agencies would be used to create RFK Jr.'s new Administration for a Healthy America. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser